CSL on Track for Lowest Close Since 2017 Following Profit Warning -- Market Talk

Dow Jones

May 11

0123 GMT - Pharmaceutical company CSL's earnings guidance downgrade and warning of impairments puts shares on course for their lowest close since early 2017. CSL's share price falls 17% to A$99.70 after interim CEO Gordon Naylor reset expectations. CSL now projects FY 2026 revenue of around US$15.2 billion and underlying net profit of US$3.1 billion when currency swings are stripped out. CSL said "a normalization of channel inventory" for immunoglobulin in the U.S. would hit revenue by around US$300 million. Separately, the value of the China albumin market has declined and would hit revenue by an additional US$200 million. CSL signaled some US$5 billion of impairments. In February, CSL had forecast underlying profit growth of 4%-7% excluding one-off costs at constant currency and revenue growth of 2%-3%. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

May 10, 2026 21:23 ET (01:23 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2634420700"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634420700\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634420700?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634420700","market":"other","top_or_hot":-1,"title":"CSL on Track for Lowest Close Since 2017 Following Profit Warning -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0123 GMT - Pharmaceutical company CSL's earnings guidance downgrade and warning of impairments puts shares on course for their lowest close since early 2017. CSL's share price falls 17% to A$99.70 after interim CEO Gordon Naylor reset expectations. CSL now projects FY 2026 revenue of around US$15.2 billion and underlying net profit of US$3.1 billion when currency swings are stripped out. CSL said \"a normalization of channel inventory\" for immunoglobulin in the U.S. would hit revenue by around US$300 million. Separately, the value of the China albumin market has declined and would hit revenue by an additional US$200 million. CSL signaled some US$5 billion of impairments. In February, CSL had forecast underlying profit growth of 4%-7% excluding one-off costs at constant currency and revenue growth of 2%-3%. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 10, 2026 21:23 ET (01:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL on Track for Lowest Close Since 2017 Following Profit Warning -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL on Track for Lowest Close Since 2017 Following Profit Warning -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-11 09:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0123 GMT - Pharmaceutical company CSL's earnings guidance downgrade and warning of impairments puts shares on course for their lowest close since early 2017. CSL's share price falls 17% to A$99.70 after interim CEO Gordon Naylor reset expectations. CSL now projects FY 2026 revenue of around US$15.2 billion and underlying net profit of US$3.1 billion when currency swings are stripped out. CSL said \"a normalization of channel inventory\" for immunoglobulin in the U.S. would hit revenue by around US$300 million. Separately, the value of the China albumin market has declined and would hit revenue by an additional US$200 million. CSL signaled some US$5 billion of impairments. In February, CSL had forecast underlying profit growth of 4%-7% excluding one-off costs at constant currency and revenue growth of 2%-3%. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 10, 2026 21:23 ET (01:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169589451.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634420700","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634420700","pubTimestamp":1778462580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0123 GMT - Pharmaceutical company CSL's earnings guidance downgrade and warning of impairments puts shares on course for their lowest close since early 2017. CSL's share price falls 17% to A$99.70 after interim CEO Gordon Naylor reset expectations. CSL now projects FY 2026 revenue of around US$15.2 billion and underlying net profit of US$3.1 billion when currency swings are stripped out. CSL said \"a normalization of channel inventory\" for immunoglobulin in the U.S. would hit revenue by around US$300 million. Separately, the value of the China albumin market has declined and would hit revenue by an additional US$200 million. CSL signaled some US$5 billion of impairments. In February, CSL had forecast underlying profit growth of 4%-7% excluding one-off costs at constant currency and revenue growth of 2%-3%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK4086":"建筑产品","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7067":"生物科技","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK7511":"ESG概念","CSL.AU":"CSL LIMITED","CSL":"卡莱尔伙伴","BK7501":"新冠治疗股","BK7508":"医药生物股"},"translate_title":"CSL在盈利预警后有望创下2017年以来的最低收盘价——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1.5},"content_text":"0123 GMT - Pharmaceutical company CSL's earnings guidance downgrade and warning of impairments puts shares on course for their lowest close since early 2017. CSL's share price falls 17% to A$99.70 after interim CEO Gordon Naylor reset expectations. CSL now projects FY 2026 revenue of around US$15.2 billion and underlying net profit of US$3.1 billion when currency swings are stripped out. CSL said \"a normalization of channel inventory\" for immunoglobulin in the U.S. would hit revenue by around US$300 million. Separately, the value of the China albumin market has declined and would hit revenue by an additional US$200 million. CSL signaled some US$5 billion of impairments. In February, CSL had forecast underlying profit growth of 4%-7% excluding one-off costs at constant currency and revenue growth of 2%-3%. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 10, 2026 21:23 ET (01:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}